Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pharmacyclics
Pharmacyclics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
AbbVie to purchase Pharmacyclics for US$21bn
Gains access to cancer treatment Imbruvica
WuXi subsidiary in deal with Pharmacyclics
Supply arrangement follows approval of Imbruvica by US FDA
Manufacturing
Catalent to supply cancer drug capsules for commercial supply to Pharmacyclics
Following approval by the US Food and Drug Administration for the treatment of mantle cell lymphoma
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Blood cancers – ibrutinib
There is a need for new treatment options for patients whose treated chronic lymphocytic leukaemia or other B-cell malignancy has relapsed, or who do not respond to existing therapies
Subscribe now